Purchase of Salix adds gastrointestinal drugs to Valeant stable
Valeant will pay US$158 a share in cash for Salix in US$10.1 billion acquisition
New York
VALEANT Pharmaceuticals International Inc agreed to buy Salix Pharmaceuticals Ltd for about US$10.1 billion, a person with knowledge of the matter said, to add gastrointestinal drugs to its stable of offerings.
Valeant will pay US$158 a share in cash for Salix, the person said, asking not to be identified because the company hasn't announced the deal. Salix shares rose US$7.11 to US$157.85 last Friday, almost completely eliminating any premium in the purchase price.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
iPhone maker Hon Hai’s April sales rise 19% in positive signal
Worsening weather is igniting a US$25 billion market
TikTok tells advertisers: ‘We are not backing down’
EV automakers get reprieve in US tax credit rules
Nomura, Mizuho face losses on All Blue fund’s failed trades
Stablecoin Tether steps up monitoring in bid to combat illicit finance